Q4 EPS Forecast for Enanta Pharmaceuticals Cut by Analyst

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – Research analysts at HC Wainwright dropped their Q4 2026 earnings per share (EPS) estimates for shares of Enanta Pharmaceuticals in a research note issued to investors on Tuesday, May 12th. HC Wainwright analyst B. Folkes now expects that the biotechnology company will post earnings per share of ($0.80) for the quarter, down from their prior forecast of ($0.73). HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($1.98) per share. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ FY2028 earnings at ($3.24) EPS, FY2029 earnings at ($2.43) EPS and FY2030 earnings at ($2.21) EPS.

Other equities research analysts have also recently issued research reports about the stock. Rodman & Renshaw started coverage on shares of Enanta Pharmaceuticals in a research report on Thursday, March 26th. They issued a “buy” rating and a $20.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Monday, April 20th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Enanta Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.29.

Enanta Pharmaceuticals Stock Down 3.4%

Enanta Pharmaceuticals stock opened at $14.03 on Thursday. The stock has a 50-day simple moving average of $13.64 and a 200 day simple moving average of $13.53. The stock has a market capitalization of $407.14 million, a price-to-earnings ratio of -5.42 and a beta of 1.01. Enanta Pharmaceuticals has a 12-month low of $5.03 and a 12-month high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.01. Enanta Pharmaceuticals had a negative return on equity of 68.72% and a negative net margin of 89.56%.The company had revenue of $17.16 million for the quarter, compared to analyst estimates of $17.03 million.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. AQR Capital Management LLC lifted its stake in Enanta Pharmaceuticals by 674.7% in the first quarter. AQR Capital Management LLC now owns 357,109 shares of the biotechnology company’s stock valued at $1,971,000 after buying an additional 311,010 shares during the period. Millennium Management LLC boosted its stake in Enanta Pharmaceuticals by 50.2% during the 1st quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock worth $7,435,000 after acquiring an additional 449,945 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in Enanta Pharmaceuticals by 5.3% during the first quarter. Goldman Sachs Group Inc. now owns 130,410 shares of the biotechnology company’s stock valued at $720,000 after purchasing an additional 6,549 shares during the period. Invesco Ltd. grew its holdings in Enanta Pharmaceuticals by 4.3% during the second quarter. Invesco Ltd. now owns 62,884 shares of the biotechnology company’s stock valued at $475,000 after purchasing an additional 2,607 shares during the period. Finally, Marshall Wace LLP increased its stake in Enanta Pharmaceuticals by 0.8% in the second quarter. Marshall Wace LLP now owns 857,412 shares of the biotechnology company’s stock valued at $6,482,000 after purchasing an additional 6,522 shares in the last quarter. Institutional investors and hedge funds own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct?acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.